News|Articles|November 30, 2012

FDA approves cabozantinib to treat rare type of thyroid cancer

FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME